Ventana Biotech, Inc. (VNTA)
Ventana Biotech, Inc. operates in the Shell Companies industry of the Financial Services sector, headquartered in Denver, CO, US. The stock last traded at $0.05, up 48.48% on the session, giving a market capitalisation of $134,914. On trailing twelve-month figures it carries a trailing P/E of 30.62, a net margin of 75.2%. Its beta of -3.53 implies it has historically moved less than the broad market.
Ventana Biotech, Inc. is an emerging biotechnology enterprise focused on the lifecycle of drug candidates for personalized medicine, encompassing the identification, assessment, acquisition, development, and eventual commercialization through partnerships of relevant intellectual property. The company's primary therapeutic area is addressing obesity and its associated medical conditions. Notably, Ventana holds proprietary rights to a medicated chewing gum formulation that integrates an extract of hoodia gordonii and 2-hydroxyoleic acid. This unique composition is intended for the management of obesity, hypertension, and various other metabolic disorders. Ventana is actively engaged in developing these appetite-suppressant chewing gums into distinct products: a lower-dosage version aimed at the over-the-counter market, and a higher-dosage variant slated for distribution via pharmacists. The lower-strength product is expected to be retailed in drugstores and health food establishments. Established in 1989, Ventana Biotech, Inc. operates from Butschwil, Switzerland. The company adopted its current name in October 2008, having previously been known as Personalica, Inc.
Ventana Biotech, Inc. is most often compared with the following Financial Services names: